SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The Company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. 

For additional information, please visit www.splice.bio.